British Journal of Cancer · 1999 · 70 citations · 29 references
MedicineImmunologyOncologyAntibody EngineeringCancer ImmunologyImmunotherapyAntibody Specificity EngineeringBiologic TherapeuticsBiologic TherapiesCancer ImmunotherapyDisplay Technologies For Antibody SelectionHybridoma TechnologyHodgkin Lymphoma TherapyHodgkin Lymphoma TreatmentMurine Hybridoma SystemsPhage Display LibrariesPhage Display ScreeningSingle-chain Variable Fragment ConstructionSingle-chain Variable Fragment LibrariesSingle-chain Variable Fragments
The human CD30 receptor is highly overexpressed on the surface of Hodgkin Reed-Sternberg cells and has been shown to be an excellent target for selective immunotherapy using monoclonal antibody-based agents such as immunotoxins. To construct a new recombinant immunotoxin for possible clinical use in patients with Hodgkin's lymphoma, we have chosen the murine anti-CD30 hybridoma Ki-4 to generate a high-affinity Ki-4 single-chain variable fragment (scFv). Hybridoma V-genes were polymerase chain reaction-amplified, assembled, cloned and expressed as a mini-library for display on filamentous phage. Functional Ki-4 scFv were obtained by selection of binding phage on the Hodgkin lymphoma-derived, CD30-expressing cell line L540Cy. The selected recombinant Ki-4 scFv was shown to specifically bind to an overlapping epitope on the CD30 antigen with binding kinetics similar to those of the original antibody. The Ki-4 scFv was subsequently fused to a deletion mutant of Pseudomonas exotoxin A (ETA'). The resulting immunotoxin Ki-4(scFv)-ETA' specifically binds to CD30+ L540Cy cells and inhibits the protein synthesis by 50% at a concentration (IC50) of 43 pM. This recombinant immunotoxin is a promising candidate for further clinical evaluation in patients with Hodgkin's lymphoma or other CD30+ malignancies.
29
James D. Marks, Hennie R. Hoogenboom, Timothy P. Bonnert et al. · Journal of Molecular Biology · 1991 · 1.6K citations